The medical device tax enacted as part of the Affordable Care Act won’t have the deleterious effects predicted by the medtech industry, according to the chief economist of a non-partisan think tank.
Medical device companies and their lobbyists have long claimed that the 2.3% tax on U.S. sales of prescribed medical devices will drive jobs overseas, increase prices and stifle medtech innovation.